logo

For the Inventor, By the Inventor

Berlin, Germany

Herbert H Schneider

USPTO Granted Patents = 36


Average Co-Inventor Count = 5.5

ph-index = 9

Forward Citations = 205(Granted Patents)


Company Filing History:

goldMedal33 out of 1,384 
 
Schering Aktiengesellschaft
 patents
silverMedal1 out of 192 
 
Bayer Schering Pharma Ag
 patents
bronzeMedal1 out of 1 
 
Scnering Aktiengesellschaft
 patent
4. 1 out of 832,843 
Other
 patents

Years Active: 1980-2010

Loading Chart...
Loading Chart...
36 patents (USPTO):Explore Patents
1. 7683081 - 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives (2010-03-23),
2. 7196202 - 1-aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives (2007-03-27),
3. 6962932 - 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives (2005-11-08),
4. 6903126 - 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives (2005-06-07),
5. 6855714 - 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives (2005-02-15),
6. 6284779 - Heteroaromatic compounds (2001-09-04),
7. 6143733 - Quinoxalinedione derivatives, their production and use in pharmaceutical (2000-11-07),
8. 6136805 - Quinoxaline dione derivatives, their production and their use in (2000-10-24),
9. 6117895 - Pharmaceutical preparations for TNF inhibition (2000-09-12),
10. 6025376 - Chiral methylphenyloxazolidinones (2000-02-15),
11. 6011060 - Chiral phenyldihydrofuranones as PDE-IV inhibitors (2000-01-04),
12. 5700808 - 5- or 6-substituted .beta.-carboline-3-carboxylic acid esters (1997-12-23),
13. 5698555 - Hetaryloxy-.beta.-carbolines, their production and use in pharmaceutical (1997-12-16),
14. 5614509 - Pharmaceutical agents for preventing the development of tolerance during (1997-03-25),
15. 5543519 - 3-aryl or 3-hetaryl-.beta.-carbolines, their production and use in (1996-08-06),

Title: Herbert H. Schneider - Innovator in Pharmaceutical Chemistry

Introduction

Herbert H. Schneider, based in Berlin, Germany, is an accomplished inventor known for his significant contributions to pharmaceutical chemistry. With a remarkable portfolio of 36 patents, Schneider has dedicated his career to the development of innovative pharmaceutical agents targeting various health conditions.

Latest Patents

Schneider's latest patents include novel 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, which have potential uses in treating and preventing diseases associated with microglia activation and T-cell-mediated immunological disorders. His work describes the production and application of these new benzimidazole derivatives in pharmaceutical preparations, emphasizing their therapeutic potential. Additionally, he has developed 1-aryl-2-N-, S-, or O-substituted benzimidazole derivatives, which also target similar health issues. The inventions revolve around the general formula of these compounds and their application in creating effective pharmaceutical agents.

Career Highlights

Throughout his career, Herbert H. Schneider has made significant strides in the pharmaceutical industry. He has notably worked at Schering Aktiengesellschaft, a global leader in pharmaceuticals, where he honed his expertise and contributed to various research initiatives aimed at drug development.

Collaborations

Schneider has collaborated with esteemed professionals in the field, including colleagues Andreas Huth and Dieter Seidelmann. These partnerships have bolstered his innovative efforts and have facilitated advancements in the pharmaceutical domain.

Conclusion

Herbert H. Schneider stands out as a prominent figure in pharmaceutical innovation. His extensive experience and portfolio of patents underscore his commitment to enhancing healthcare through the development of novel therapeutic agents. As the pharmaceutical landscape continues to evolve, Schneider's contributions will undoubtedly leave a lasting impact.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…